Trial Profile
A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Treatment With Single and Repeat Doses of Inhaled RV6153 in Healthy Subjects and Subjects With Stable Asthma.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs RV 6153 (Primary)
- Indications Asthma
- Focus Adverse reactions; Pharmacodynamics
- Sponsors RespiVert
- 03 Mar 2016 Status changed from active, no longer recruiting to discontinued, as reported by ClinicalTrials.gov.
- 13 Jan 2016 Planned End Date changed from 1 Apr 2016 to 1 Feb 2016 as reported by ClinicalTrials.gov.
- 13 Jan 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Feb 2016 as reported by ClinicalTrials.gov.